Newswise — The American Association for Cancer Research is currently accepting nominations for the prestigious Pezcoller Foundation-AACR International Award for Cancer Research.
This award, now in its 13th year, recognizes an individual scientist or co-nominated scientists of international renown who have made a major scientific discovery in basic or translational cancer research, and whose ongoing work holds promise for continued substantive contributions to progress in the field of cancer.
The Award includes an unrestricted grant of €75,000 and a commemorative plaque.
The recipient of the Pezcoller Foundation-AACR International Award for Cancer Research will give a 50-minute lecture at the AACR 101st Annual Meeting 2010, which will be held in Washington, D.C., from April 17 to 21, and also present the Fifth Annual Stanley J. Korsmeyer Lecture in Padua, Italy, just prior to the official award ceremony in Trento, Italy, in early May 2010.
Nominations must be submitted online at https://proposalcentral.altum.com no later than Tuesday, September 15, 2009.
The Pezcoller Foundation was established in 1980 by Professor Alessio Pezcoller, a dedicated Italian surgeon who made important contributions to medicine during his career. Through Pezcoller’s foresight, vision and generous gift in support of the formation of the Foundation, he encouraged others to join this effort in sustaining the work of the Foundation. He has inspired scientists around the world to make significant advances in cancer research. In addition to sponsoring this prestigious award, the Foundation also sponsors a series of symposia, publishes a journal and supports awards for early-career scientists from Europe who have submitted highly rated abstracts for presentation at the AACR Annual Meeting.
The 2009 Award Winner, Napoleone Ferrara, M.D., was recognized for his groundbreaking research in the mechanisms of tumor angiogenesis. Ferrara and his colleagues at Genentech, Inc. reported the isolation and cloning of vascular endothelial growth factor (VEGF). This groundbreaking discovery led to the development of bevacizumab (Avastin), the first antibody directed at VEGF, which suppresses angiogenesis and tumor growth. After years of clinical trials, the FDA approved bevacizumab in 2004 for the treatment of advanced lung, colon and breast cancers in combination with chemotherapy.
For more information on eligibility criteria, the nomination process and other details about the Pezcoller Foundation-AACR International Award for Cancer Research, please visit www.aacr.org/page14329.aspx. Additional inquiries should be directed to Monique P. Eversley at firstname.lastname@example.org.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.